← Back to Clinical Trials
Recruiting NCT06603506

NCT06603506 Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06603506
Status Recruiting
Phase
Sponsor Centre Francois Baclesse
Condition Endometrial Cancer
Study Type OBSERVATIONAL
Enrollment 16 participants
Start Date 2024-11-21
Primary Completion 2027-10-15

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
tumour and blood samples

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 16 participants in total. It began in 2024-11-21 with a primary completion date of 2027-10-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study comprises 3 stages: 1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.

Eligibility Criteria

Inclusion Criteria: * Patient aged 18 years or more * Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment. * Patient with localized endometrial cancer, presenting: * A high-grade endometrioid histological type and/or * P53 mutation and/or * a non-endometrioid histological type regardless of P53 status. * Patient affiliated to a social security scheme * Information and signature of informed consent prior to any specific study procedure Exclusion Criteria: * Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin). * Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.

Contact & Investigator

Central Contact

Gwenn LE GALL, Medical Doctor

✉ g.legall@baclesse.unicancer.fr

📞 +33231455050

Frequently Asked Questions

Who can join the NCT06603506 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Endometrial Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06603506 currently recruiting?

Yes, NCT06603506 is actively recruiting participants. Contact the research team at g.legall@baclesse.unicancer.fr for enrollment information.

Where is the NCT06603506 trial being conducted?

This trial is being conducted at Caen, France.

Who is sponsoring the NCT06603506 clinical trial?

NCT06603506 is sponsored by Centre Francois Baclesse. The trial plans to enroll 16 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology